Botulinum Toxin Market Report

Botulinum Toxin Market Analysis By Type (Botulinum Toxin Type A, Botulinum Toxin Type B), By End Use (Therapeutic, Aesthetic), By Region (North America, Europe, Asia Pacific, Latin America, MEA), And Segment Forecasts, 2013 - 2025

Published: January 2017  |  90 Pages  |  Format: PDF  |  Report ID: GVR-1-68038-355-3

Industry Insights

The global botulinum toxin (BNT) market was valued at USD 3.4 billion in 2015 and is expected to grow at a CAGR of 7.9% over the forecast period. Growing population aged between 25 to 65 years and increasing demand for minimally invasive or non-invasive procedures are the prime factors fueling the growth of the global market.

BNT is a neurotoxin and has seven different antigenic forms namely BNT - A, B, C, D, E, F and G which are produced by an anaerobic bacterium, Clostridium botulinum. BNT is widely used for the aesthetic purposes. Presently, a few products of BNT - A and only one product of BNT - B are commercially available in the market. However, heavy investment on R&D projects to develop the therapeutic use of botulinum toxin is creating opportunities for the expansion of its application area in the near future.

Japan botulinum toxin market, by product type, 2013 - 2025 (USD Million)

Japan botulinum toxin market

Side effects such as allergic reactions, rash, neck and back pain, difficulty in swallowing, shortness of breath and nausea are hindering the adoption of neurotoxins in therapeutics as well as cosmetic application. In addition, high cost entailed in performing such expensive procedures, and poor reimbursement coverage for products like Myobloc by Solstice Neurosciences, LLC are further hampering the growth of the market.

Product Insights

The BNTA segment is leading the global market with the largest share in 2015. This segment is expected to maintain its dominance throughout the forecast period. Various products of BNTA are commercially available in the market which includes leading brands such as Botox and Dysport. Botox has aesthetic application in moderate and severe glabellar lines removal and therapeutic application in treating severe primary axillary hyperidrosis, blepharospasm and cervical dystonia. Similarly, Xeomin is used for removal of glabellar lines and treatment of cervical dystonia and blepharospasm in some countries. 

However, it is observed that these products have few side effects such as allergic reactions, rash, nausea, neck and back pain. BNTA products are also quite expensive and involve high expenses while performing surgical procedures. Hence, such factors are hindering the growth of the market.

Application Insights

Botulinum toxin is primarily used for cosmetic (aesthetic) application in improving the facial appearance and reducing signs of aging. It is used for treating frown lines, crow’s feet lines, and glabellar lines. Thus, the aesthetic segment captured the largest market share in 2015.

Botulinum toxin (Botox) by Allergan received the U.S. FDA approval for hyperhidrosis in 2004; cervical dystonia in 2009; post-stroke upper limb spasticity in 2010; and urinary incontinence and overactive bladder in 2011. Thus, it is observed that constant R&D efforts are widening the Botox use across various indications.

In addition, other products such as Dysport and Xeomin have therapeutic applications in blepharospasm, cervical dystonia and hyperidrosis. Also, botulinum toxin B (BNTB), commercially available under the brand name, Myobloc is used for treating cervical dystonia. Considering the constantly escalating use of botulinum toxin in therapeutic applications, the therapeutic application segment is anticipated to rise significantly during the forecast period.

Global botulinum toxin market, by end use, 2015

Global botulinum toxin market

Regional Insights

North America dominated the market by capturing the largest revenue share in 2015. Higher disposable income and availability of a variety of aesthetic procedures for enhancing external appearance is pushing the demand for botulinum toxin in North America.

Asia Pacific is expected to exhibit the highest growth in the near future due to aging demographics and rising disposable income resulting in higher demand for anti-aging products. In addition, the growing social awareness regarding commercial availability of these products in Asia Pacific is anticipated to augment the growth of the market in the near future.

Competitive Outlook

Major players competing in the industry include but are not limited to Allergan, Inc.; Ipsen Group; Merz Pharma GmbH and Co. KGaA. These companies hold a strong position in the global market mainly due to strong brand identity and their commercial availability around the world.

Some other players operating in the market include Medytox,Inc.; US Worldmed,LLC; Lanzhou Institute of Biological Products Co.Ltd. and Revance Therapeutics, Inc. The competition in the market is expected to intensify in the near future since several companies are now focusing on their research endeavors in order to introduce novel therapeutic applications of the existing products.

Report Scope

Attribute

Details

Base year for estimation

2015

Actual estimates/Historical data

2013 - 2015

Forecast period

2016 - 2025

Market representation

Revenue in USD Million & CAGR from 2016 to 2025

Regional scope

North America, Europe, Asia Pacific, Latin America,& MEA

Country scope

U.S., Canada, UK, Germany, China, Japan, India, Brazil, Mexico, & South Africa

Report coverage          

Revenue, company share, competitive landscape, growth factors, trends

15% free customization scope (equivalent to 5 analyst working days)

If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization


Segments Covered in the Report

This report forecasts revenue growth at global, regional & country levels and provides an analysis on the latest trends and opportunities in each of the sub-segments from 2013 to 2025. For the purpose of this study, Grand View Research has segmented the botulinum toxin market on the basis of product, end use and region:

  • Product Outlook (Revenue, USD Million; 2013 - 2025)

    • Botulinum Toxin Type A

    • Botulinum Toxin Type B

  • End Use Outlook (Revenue, USD Million; 2013 - 2025)

    • Aesthetic

    • Therapeutics

  • Regional Outlook (Revenue, USD Million; 2013 - 2025)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • UK

    • Asia Pacific

      • China

      • Japan

    • Latin America

      • Mexico

      • Brazil

    • MEA

      • South Africa

Key questions answered by the report
Request for Customization

Choose License Type:

Single User - $3,450
Multi User - $6,450
Enterprise User - $8,450

Special Pricing & Discounts

Avail customized purchase options to meet your research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert. Request for a free product review before report purchase.

  • Custom research service

    Custom research service

    Speak to the report author to design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service excellence represented in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • BOA